# TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

> **NCT00896051** · PHASE2 · COMPLETED · sponsor: **Janssen R&D Ireland** · enrollment: 50 (actual)

## Conditions studied

- HIV Infections
- Acquired Immunodeficiency Syndrome

## Interventions

- **DRUG:** Atazanavir (ATV) 300 mg
- **DRUG:** Atazanavir (ATV) 400 mg
- **DRUG:** Ritonavir (rtv) 100 mg
- **DRUG:** Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)
- **DRUG:** Etravirine (ETR) 200 mg
- **DRUG:** Tenofovir disoproxil fumarate (TDF) 300 mg

## Key facts

- **NCT ID:** NCT00896051
- **Lead sponsor:** Janssen R&D Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00896051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00896051, "TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00896051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*